#Deviation Management
Browse all posts tagged with Deviation Management
Can You Write the Ship?
April 21, 2026 • By Paul Van Buskirk
AI can generate answers that look right—but what happens when teams lose the ability to build them on their own? In GxP environments, this isn’t just a technology risk—it’s a capability risk that shows up in execution, decision-making, and ultimately, Cost of Poor Quality.
The True Cost of a Failed Pharmaceutical Batch
April 15, 2026 • By Mike Barlow, Paul Van Buskirk
Most companies underestimate the true cost of a lost batch by 5–10×. Beyond the write-off, hidden work, capacity loss, and system disruption drive a much larger Cost of Poor Quality (COPQ) than is typically measured.
Digital Doesn’t Fix Broken Execution
April 8, 2026 • By Paul Van Buskirk
Pharmaceutical companies continue to invest heavily in digital transformation, yet operational outcomes remain unchanged. This article explains why visibility alone doesn’t improve execution—and how governance and discipline must come first.
Artificial Intelligence in GxP Environments
April 6, 2026 • By Paul Van Buskirk
Artificial Intelligence (AI) in GxP environments is not a decision-making system—it is structured decision support aligned with GAMP 5. Most organizations get this wrong, positioning AI in ways that introduce unnecessary compliance risk. This whitepaper defines the correct framework—how to apply AI with discipline, maintain human ownership of decisions, and align with regulatory expectations without increasing validation burden.
Deviation Backlogs Are Not Linear: Understanding the Hidden Factory in GMP Investigations
April 1, 2026 • By Mike Barlow
Deviation investigations are often managed as a linear workload—one record, one investigation, one unit of effort. This assumption holds only while the system operates within capacity. Once backlog forms, the system behavior changes. Effort no longer scales with the number of deviations; it expands nonlinearly as coordination, prioritization, and aging effects take over. The result is a Hidden Factory—capacity consumed not by resolving deviations, but by managing them. Understanding this shift is critical: restoring performance is not about working harder, but about re-establishing flow in a system that has crossed into exponential cost.
How to Calculate Your Facility's True COPQ (Free Calculator)
July 24, 2025 • By Mike Barlow, Paul Van Buskirk
Cost of Poor Quality (COPQ) can quietly erode margins in biopharma operations through rework, deviations, delays, and batch losses. This post breaks down the four key components of quality cost—prevention, appraisal, internal failure, and external failure—and introduces a free COPQ calculator to help you estimate the true financial impact and identify opportunities for ROI.
How To Write the Perfect Problem Statement
May 29, 2024 • By Mike Barlow
If you work in Biopharmaceutical Manufacturing or Quality, one of the best things you can do to drive reliability in GMP Manufacturing is learn how to craft a strong problem statement. In this video, we will show you how to do that. Creating a strong problem statement is pivotal in problem-solving. A well-defined problem statement sets the stage for effective GMP deviation investigation and problem solving.
What is a GMP Deviation Investigation?
August 26, 2023 • By Mike Barlow
In GMP pharmaceutical production, including biologics and cell therapy manufacturing, a GMP Deviation Investigation is the structured process used to identify, document, analyze, and resolve any unexpected events or conditions that do not comply with approved procedures, specifications, or regulatory requirements.